PharmAla Biotech Holdings, Inc. (MDMA) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 80.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: -73.52%
• EPS Growth: -172.73%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 94,290,240
• 10 Day Avg. Volume: 67,327
• 30 Day Avg. Volume: 80,259
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 52.67
• Price to Cash Flow (P/CF): -18.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

PharmAla Biotech Holdings, Inc. shows potential due to strong revenue growth and strategic corporate events. However, profitability issues and bearish technical indicators weigh on the stock's attractiveness. The company's expansion into new markets and partnerships are positive, but effective cost and cash flow management remain crucial for future success.

PharmAla Biotech Holdings, Inc. Business Overview & Revenue Model

Company Description

PharmAla Biotech Holdings, Inc. (MDMA) is a biotechnology company focused on the research, development, and commercialization of pharmaceutical products utilizing psychedelic compounds. The company primarily operates within the pharmaceutical and healthcare sectors, aiming to create innovative treatments for mental health disorders. PharmAla Biotech is committed to the ethical and sustainable development of MDMA-based therapeutics, leveraging cutting-edge scientific advancements to address unmet medical needs.

How the Company Makes Money

PharmAla Biotech Holdings, Inc. generates revenue through the development and sale of MDMA-based pharmaceutical products. The company conducts extensive research and clinical trials to ensure the efficacy and safety of its products, which are then marketed to healthcare providers and institutions. Revenue streams include the licensing of patented compounds, collaboration with research institutions, and potential partnerships with healthcare organizations for distribution and commercialization. Regulatory approvals and advancements in the understanding of psychedelic therapies contribute significantly to the company's earnings potential.

PharmAla Biotech Holdings, Inc. Financial Statement Overview

Summary

PharmAla Biotech Holdings, Inc. shows significant revenue growth, but profitability remains elusive with negative net income and EBITDA margins. A strong equity position is offset by declining stockholders' equity, and consistent negative free cash flow highlights cash management challenges.

Income Statement

PharmAla Biotech Holdings, Inc. has shown significant revenue growth in recent years, increasing from 78,070 to 1,035,297 annually. Nevertheless, the company remains unprofitable with negative net income and EBITDA margins, indicating ongoing challenges in managing operational costs effectively. The absence of EBIT suggests a need for improved cost management strategies.

Balance Sheet

The company's balance sheet reflects a strong equity position with no total debt, leading to a favorable debt-to-equity ratio. However, the decrease in stockholders' equity over time raises concerns. The equity ratio remains robust, but the company must manage liabilities to sustain financial stability.

Cash Flow

PharmAla Biotech Holdings, Inc. faces challenges in achieving positive free cash flow, with consistent negative values across the years. Operating cash flow to net income ratio indicates difficulties in converting revenue into cash flow, underscoring the need for better cash management practices to support growth.

Breakdown
Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement		Total Revenue
1.04M	532.00K	78.07K	0.00
	Gross Profit
887.44K	454.10K	75.78K	-303.00
	EBIT
0.00	-762.95K	-985.58K	-2.51M
	EBITDA
-573.36K	-710.18K	-973.45K	-2.51M
	Net Income Common Stockholders
-823.60K	-779.81K	-985.58K	-2.51M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
419.38K	195.04K	852.14K	2.47M
	Total Assets
2.90M	2.41M	2.33M	2.79M
	Total Debt
0.00	253.54K	0.00	0.00
	Net Debt
-419.38K	58.49K	-852.14K	-2.47M
	Total Liabilities
916.88K	1.03M	423.78K	138.48K
	Stockholders Equity
1.98M	1.38M	1.91M	2.66M
Cash Flow		Free Cash Flow
-547.78K	-846.39K	-1.62M	-435.76K
	Operating Cash Flow
-321.36K	-339.66K	-625.37K	-173.57K
	Investing Cash Flow
-226.42K	-506.74K	-994.87K	629.22K
	Financing Cash Flow
772.12K	189.29K	0.00	2.02M

PharmAla Biotech Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDMA, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.18, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 34.60 is Neutral, neither overbought nor oversold. The STOCH value of 8.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MDMA.

PharmAla Biotech Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.31B	3.39	-40.42%	2.90%	18.11%	2.25%
TRIP	49 Neutral	C$14.03M	―	-30.44%	―	13.57%	-14.29%
MDMA	48 Neutral		―	-78.49%	―	-73.52%	-172.73%
PSYC	44 Neutral	$4.33M	―	-59.47%	―	94.07%	25.00%
CYBN	37 Underperform	$1.97M	―	-58.79%	―	―	51.37%

PharmAla Biotech Holdings, Inc. Corporate Events

PharmAla Biotech Ships LaNeo™ MDMA to University of Washington, Appoints New CCO

PharmAla Biotech Holdings Inc. has successfully completed an international shipment of its LaNeo™ MDMA to the University of Washington for clinical research, highlighting the company’s role in supporting important human research studies in the United States. Despite the successful delivery, the company acknowledges the ongoing risk posed by US-Canada cross-border trade uncertainties and advocates for tariff exemptions on investigational drug products for US-funded research. Additionally, PharmAla has appointed Ali Taghva as Chief Commercial Officer to enhance its commercial operations.

PharmAla Biotech Expands into Netherlands with Exclusive Distribution Deal

PharmAla Biotech Holdings Inc. has entered into an exclusive distribution agreement with Duchefa Farma B.V. to distribute its LaNeo MDMA in the Netherlands. This strategic partnership is expected to open new market opportunities for PharmAla, leveraging Duchefa’s strong presence and relationships in the European market. The agreement includes annual purchase minimums and provisions for increased demand following regulatory changes in the Netherlands, potentially enhancing PharmAla’s industry positioning and contributing to the acceptance of MDMA-Assisted Therapy for PTSD treatment.

PharmAla Ships LaNeo™ MDMA to UCLA for Schizophrenia Trial

PharmAla Biotech Holdings Inc. has successfully completed the shipment of its LaNeo™ MDMA to UCLA for a clinical trial investigating schizophrenia. This marks the first shipment of MDMA capsules across the American/Canadian border, highlighting the company’s role in addressing the unmet need for MDMA in the United States for clinical trial use. The trial, led by Dr. Bershad and Dr. Marder, faced challenges due to regulatory approvals, but PharmAla is committed to supporting the research, which could significantly contribute to the scientific understanding of MDMA.

PharmAla Advances MDMA Trial for Military PTSD Treatment

PharmAla Biotech Holdings Inc. has announced the progression of its contract with the University of Texas Health Science Center at San Antonio, funded by the Defense Appropriations Act. This contract involves the development of a new 20mg clinical drug product dose of LaNeo™ MDMA, which will be used in a trial to treat PTSD in active-duty military personnel. The trial, part of the STRONG STAR Consortium, aims to explore MDMA-Assisted Therapy’s effects on this novel patient population. This collaboration highlights PharmAla’s commitment to supporting military psychological health research and could significantly impact treatment options for military personnel.

PharmAla Biotech Strengthens Advisory Team with New Agreement

PharmAla Biotech Holdings Inc. has entered into an advisory agreement with shareholder Matthew Azrieli, who is expected to aid the company in its expanding U.S. clinical trials business and other growth markets. The agreement includes potential performance-based rewards for Azrieli, aimed at bolstering media, market, and investment advisory efforts. This strategic move is likely to enhance PharmAla’s market position and operational growth, particularly in the U.S., potentially benefiting its stakeholders.

PharmAla Biotech Reports Robust Financial Growth and Strategic Partnerships in Fiscal 2024

PharmAla Biotech Holdings Inc. reported a significant financial performance for the fiscal year ended November 30, 2024, with a notable 95% revenue growth year-over-year, driven by increased MDMA product sales. The company experienced a slowdown in SAP revenue due to a transition to a new distribution partner but saw strong growth in clinical trial sales. The financial boost from investor confidence and strategic partnerships is expected to enhance the company’s market presence and meet rising demand, indicating promising future growth.